Tools   Select Another Resource Report Type

https://repository.niddk.nih.gov/study/67

Clinical trial under the Urinary Incontinence Treatment Network to compare the treatment success for two surgical procedures that are frequently used and have similar cure rates, yet have not been compared directly to each other in a large, rigorously conducted randomized trial. The secondary aims of the trial are to compare other outcomes for the two surgical procedures, including quality of life, sexual function, satisfaction with treatment outcomes, complications, and need for other treatment(s) after surgery. Follow-up will be a minimum of two years and up to four years.

Proper citation: SISTEr (RRID:SCR_001542) Copy   

•   Source: SciCrunch Registry

http://www.immunetolerance.org/

International clinical research consortium dedicated to the clinical evaluation of novel tolerogenic approaches for the treatment of autoimmune diseases, asthma and allergic diseases, and the prevention of graft rejection. They aim to advance the clinical application of immune tolerance by performing high quality clinical trials of emerging therapeutics integrated with mechanism-based research. In particular, they aim to: * Establish new tolerance therapeutics * Develop a better understanding of the mechanisms of immune function and disease pathogenesis * Identify new biomarkers of tolerance and disease Their goals are to identify and develop treatment game changers for tolerance modulating therapies for the treatment of immune mediated diseases and disabling conditions, and to conduct high quality, innovative clinical trials and mechanistic studies not likely to be funded by other sources or to be conducted by private industry that advance our understanding of immunological disorders. In the Immune Tolerance Network's (ITN) unique hybrid academic/industry model, the areas of academia, government and industry are integral to planning and conducting clinical studies. They develop and fund clinical trials and mechanistic studies in partnership. Their development model is a unique, interactive process. It capitalizes on their wide-ranging, multidisciplinary expertise provided by an advisory board of highly respected faculty from institutions worldwide. This model gives investigators special insight into developing high quality research studies. The ITN is comprised of leading scientific and medical faculty from more than 50 institutions in nine countries worldwide and employs over 80 full-time staff at the University of California San Francisco (UCSF), Bethesda, Maryland and Benaroya Research Institute in Seattle, Washington.

Proper citation: Immune Tolerance Network (ITN) (RRID:SCR_001535) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/81

Multi-center, randomized controlled study designed to determine if continuing interferon long term over several years will suppress the Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation. Patient enrollment began in 2000 and was completed in 2003 at 10 clinical centers, which were supported by a data coordinating center, virological testing center, and central sample repository. Patients with chronic hepatitis C and advanced fibrosis or cirrhosis on liver biopsy who failed to respond to a previous course of interferon alfa were enrolled in this study. Patients were initially treated with a 24-week course of peginterferon alfa-2a and ribavirin. Patients who remained hepatitis C virus RNA positive were then randomized to receive maintenance, low-dose peginterferon or to be followed on no treatment. Liver biopsies were done before enrollment and after 2 and 4 years of treatment or follow-up. The endpoints were development of cirrhosis, hepatic decompensation, hepatocellular carcinoma, death, or liver transplantation. 1050 patients were randomized and followed through the 4 year randomized phase of the trial and as long as 4 years off treatment. Serum samples collected at multiple time points, DNA and liver tissue are available for scientific investigation.

Proper citation: HALT-C Trial (RRID:SCR_001534) Copy   

•   Source: SciCrunch Registry

http://talasso.cnb.csic.es/

Tool for quantification of human miRNA-mRNA Interactions. TaLasso is also available as Matlab or R code.

Proper citation: TaLasso (RRID:SCR_001726) Copy   

•   Source: SciCrunch Registry

https://www.uniklinik-freiburg.de/mr-en/research-groups/diffperf/fibertools.html

Implemented under MATLAB, this DTI image processing toolbox provides import-filters for several MR file standards, a processing unit to calculate the diffusion tensors; several GUI based tools to calculate fiber tracks and to evaluate the DTI dataset. The results can be filed as images with 3D impression or can be logged in formatted ASCII files. Tools and features: * DTI Processing Unit: Calculates the diffusion tensors and their eigenvalues and eigenvectors. Different file formats are supported (like DICOM, Bruker, binary files, Matlab structures). The standard SIEMENS and GE diffusion encoding schemes are supported; other schemes have to be defined in a separate text, .m or .mat file. * FiberTracking: ** Fiber tracking is realized by using the FACT algorithm (Mori et al., Annal. Neurol 1999). ** Probabilistic tracking realized by using the PiCo (Parker et al., JMRI 2003) approach but with DTI data as basis. It is possible to extract pathways between two seeds by combining two maps (Kreher et al., NeuroImage 2008). ** Global Fiber Tracking on basis of HARDI or DTI data. The method is based on the approach reported in (Marco Reisert et al: Global fiber reconstruction becomes practical. NeuroImage 54(2):955-62) * FiberViewer: ** Visualization and Navigation through different data modalities like DTI maps, fiber tracks, diffusion main directions. ** Supports different kinds of DTI maps (e.g. FA, Trace, lambda images ) ** Creation and manipulation of mask based ROIs. ** Selection of streamline fibers ** Visualization of probabilistic fiber tracking results ** Documentation by logging statistics of ROIs and fiber tracks into text files. ** Import/Export from/to ANALYZE or Nifti * 3D Visualizer: Visualization of map slices, ROIs, and fiber tracks with 3D impression. * Batch Editor: Automatic processing of high amounts of data. Possibility to link processing with SPM8 easily.

Proper citation: DTI and Fibertools Software Package (RRID:SCR_001641) Copy   

•   Source: SciCrunch Registry

http://www.oege.org/

Portal for researchers to locate information relevant to interpretation and follow-up of human genetic epidemiological discoveries, including: a range of population and case and family genetic epidemiological studies, relevant gene and sequence databases, genetic variation databases, trait measurement, resource labs, journals, software, general information, disease genes and genetic diversity.

Proper citation: Online Encyclopedia for Genetic Epidemiology studies (RRID:SCR_001825) Copy   

•   Source: SciCrunch Registry

http://toc.lbg.ac.at/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 31,2025. The projected cluster includes the LBIs for Applied Cancer Research, Clinical Oncology and Photodynamic Therapy, Gynecology and Gynecologic Oncology, Stem Cell Transplantation and Surgical Oncology. The aim of the projected cluster Translational Oncology is the cooperative investigation of genetic and molecular biological characteristics of the tumor cells involved in minimal residual disease (MRD) in vitro and translation of the experimental and diagnostic results into the clinical practice involving therapeutic modalities with the newest generation of antitumoral drugs. Minimal residual disease is the designation for the occurrence of a low number of tumor cells remaining clinically undetected following curative therapy that give rise to tumor relapses. MRD is a central question in cancer therapy, since a major subpopulation of patients which underwent curative resection and therapy ultimately relapse and would have received more aggressive adjuvant therapy, provided that residual disease had been clearly proven. Otherwise low-risk patients would have not been treated aggressively in an adjuvant setting. MRD can be detected by methods in bone marrow or by extremely sensitive PCR (polymerase-chain-reaction)-based methods in peripheral blood. PCR-based methods allow for the characterization of tumor-specific gene expression in circulating tumor cells and thereby provide additional information in regard to malignity of cells and prognosis. The different participating institutions have extensive experience in patient care, organization of clinical studies and laboratory investigation. In particular, expert knowledge in stem cell transplantation and histological detection of MRD, multicentric clinical testing of new anticancer drugs, specialized treatment of various selected tumor entities such as neuroendocrine tumors, gene expression analysis of circulating tumor cells and tumor signatures, and in vitro characterization of chemosensitivity as well as tumor cell biology have been acquired at the individual LBIs in the past and are complementary to each other to be combined in a larger cluster structure. The detection of circulating tumor cells will be supported by ongoing EU (OVCAD OVarian CAncer Diagnosis) and GenAU projects aiming at identification of ovarian cancer cells in the blood. The assessment of methylated DNA sequences (suppressor genes) in peripheral blood as an indicator of MRD can be performed with the help of OncoLab Diagnostics GmbH. Cooperative action in this cluster, using a common tumor bank/clinical data collection and the combined clinical and experimental efforts are the base for the execution of the presented MRD project.

Proper citation: Ludwig Boltzmann Cluster Translationale Onkologie (RRID:SCR_000020) Copy   

•   Source: SciCrunch Registry

http://www.psygenet.org/web/PsyGeNET/menu;jsessionid=y6kqy9lqlxymr0nwwkkfo84

Knowledge platform on psychiatric disorders and their genes. Resource for exploratory analysis of psychiatric diseases and their associated genes. PsyGeNET is composed of database and set of analysis tools and is the result of the integration of information from DisGeNET and data extracted from the literature by text mining, followed by curation by domain experts.

Proper citation: PsyGeNET (RRID:SCR_014406) Copy   

•   Source: SciCrunch Registry

https://portal.bsc.gwu.edu/web/lifemoms

A consortium whose overall goal is to identify effective behavioral and lifestyle interventions that will improve weight, glycemic control and other pregnancy-related outcomes in obese and overweight pregnant women, and determine whether these interventions reduce obesity and metabolic abnormalities in their children. The study/consortium is comprised of seven clinical centers, with each clinical center conducting its own trial. Additional information on the consortium and individual trials is located in the Consortium Summaries tab.

Proper citation: Lifestyle Interventions for Expectant Moms (LIFE-Moms) (RRID:SCR_014376) Copy   

•   Source: SciCrunch Registry

https://ndar.nih.gov/tools_guid_tool.html

A customized software application that generates a Global Unique Identifier for each study participant. The GUID is a universal subject ID that allows researchers to share data specific to a study participant without exposing personally identifiable information (PII). The GUID has been approved by the NIH Office of General Counsel.

Proper citation: GUID Tool (RRID:SCR_014530) Copy   

•   Source: SciCrunch Registry

https://www.qut.edu.au/research/research-projects/landmark-biobanks

A repository of human tissue samples collected during the LANDMark study (Longitudinal Assessment of Neuropathy in Diabetes using novel ophthalmic markers). The LANDMark Biobank longitudinal dataset contains blood and tissue (skin) samples and matching detailed phenotypic data of three microvascluar complications of type 1 diabetes: neuropathy, nephropathy and retinopathy.

Proper citation: LANDMark BioBanks (RRID:SCR_014534) Copy   

•   Source: SciCrunch Registry

http://www.celllineauthentication.com/

A material analysis service of the commercial organization Genetica DNA Laboratories which provides authentication of human cancer cell lines, stem cell lines and xenografts utilizing STR DNA technology.

Proper citation: Cell Line Authentication Testing (RRID:SCR_014504) Copy   

•   Source: SciCrunch Registry

http://www.brainsimagebank.ac.uk

A searchable collection of anonymised images and associated clinical data. It includes normal individuals at all ages (from prenatal to old age). The image bank contains integrated data sets already collected as part of research studies which include control subjects. New data is added as they become available.

Proper citation: BRAINS Imagebank (RRID:SCR_014576) Copy   

•   Source: SciCrunch Registry

http://ibrain.nuaa.edu.cn/

Brain research group affiliated with the Nanjing University of Aeronautics and Astronautics (NUAA) in China. The main research interests of iBRAIN include developing methods in machine learning, data mining, neural computation, and related areas for decoding brain functions or recognizing brain disease. Research related code and datasets can be found on the main site.

Proper citation: iBRAIN (RRID:SCR_014691) Copy   

•   Source: SciCrunch Registry

https://sites.google.com/ucsd.edu/drc/home

Research center across five institutions for clinical research in diabetes. Collaborators include UC San Diego's School of Medicine, Salk Institute, Cedars-Sinai Medical Center, UC Los Angeles' School of Medicine, and LA Biomedical Research Center.

Proper citation: University of California San Diego - University of California Los Angeles Diabetes Research Center (RRID:SCR_015100) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/shp/drc/

Research center which operates in collaboration with the University of Alabama Birmingham Comprehensive Diabetes Center to promote excellence in diabetes research and patient care. The DRC supports the areas of animal physiology, human biology and intervention and translational research. It focuses on developing new methods to treat, prevent, and ultimately cure diabetes and its complications.

Proper citation: University of Alabama at Birmingham Diabetes Research Center (RRID:SCR_015107) Copy   

•   Source: SciCrunch Registry

https://diabetes.med.umich.edu/partners/michigan-diabetes-research-center-mdrc

Multidisciplinary unit of the University of Michigan funded by the National Institute of Diabetes and Digestive and Kidney Diseases/National Institute of Health. Promotes new discoveries and enhance scientific progress through the support of basic and clinical research related to diabetes, its complications, and related disorders. Creates environment that supports innovative research; attracts and retains early stage investigators and investigators new to diabetes research; provides core services that leverage funding and unique expertise; fosters interdisciplinary collaborations; raises awareness and interest in fundamental and clinical diabetes research at their institutions, as well as locally, regionally, and nationally.

Proper citation: Michigan Diabetes Research Center (RRID:SCR_015112) Copy   

•   Source: SciCrunch Registry

http://www.baderc.org

Consortium of laboratory-based and clinical investigators who research etiology, pathogenesis, treatment and cure of type 1 and type 2 diabetes, and their associated microvascular and atherosclerotic complications.

Proper citation: Boston Area Diabetes Endocrinology Research Center (RRID:SCR_015072) Copy   

•   Source: SciCrunch Registry

http://www.einstein.yu.edu/centers/diabetes-research/

Research center that facilitates the research of diabetes and related studies in obesity, metabolism and endocrinology

Proper citation: Einstein-Mount Sinai Diabetes Research Center (RRID:SCR_015070) Copy   

•   Source: SciCrunch Registry

http://aldconnect.org

Group whose goal is to improve health outcomes for individuals with X-linked adrenoleukodystrophy by raising disease awareness, improving education, providing support for and information to patients, and performing clinical ALD research.

Proper citation: ALD Connect (RRID:SCR_015035) Copy   

•   Source: SciCrunch Registry